Currently Viewing:

First PD-L1 Inhibitor Approved as Second-Line Treatment for NSCLC

Surabhi Dangi-Garimella, PhD
Atezolizumab, an inhibitor of the programmed death ligand-1 protein, has been approved for the treatment of patients with non-small cell lung cancer who failed to respond to treatment with platinum-based chemotherapy.
Atezolizumab (Tecentriq), a monoclonal antibody that inhibits the programmed death ligand-1 (PD-L1) protein, has been approved for the treatment of patients whose non-small cell lung cancer (NSCLC) failed to respond to treatment with platinum-based chemotherapy. Notably, the treatment was administered regardless of PD-L1 expression in the patient’s tumor.

The approval follows an FDA review of results from the phase 3 OAK and phase 2 POPLAR trials. OAK—a global, multicenter, open-label, randomized study—evaluated atezolizumab against docetaxel in 1225 patients with advanced or metastatic NSCLC who had failed on platinum-based chemotherapy. Patients with squamous and non-squamous form of the disease were randomized to receive intravenous atezolizumab at 1200 mg every 3 weeks, or intravenous docetaxel at 75 mg/m2, every 3 weeks. The median overall survival (OS) following primary analysis in 850 patients was 13.8 (range, 11.8-15.7) months in the atezolizumab-treated cohort, compared with 9.6 (range, 8.6-11.2) months in the docetaxel-treated cohort (hazard ratio [HR], 0.74; P = .0004).

The POPLAR study—a global, multicenter open-label, randomized phase 2 study compared response to docetaxel versus atezolizumab in patients with previously treated locally advanced or metastatic NSCLC. The trial measured OS as the primary endpoint and progression-free survival (PFS), objective response rate (ORR), and safety as secondary endpoints. The median OS for patients in the atezolizumab arm was 12.6 (range, 9.7-16.0) months compared with 9.7 (range, 8.6-12.0) months following docetaxel treatment (HR, 0.69).

The most common (greater than or equal to 20%) adverse reactions with atezolizumab were fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation. The most common (greater than or equal to 2%) grade 3-4 adverse events in patients treated with atezolizumab were dyspnea, pneumonia, hypoxia, hyponatremia, fatigue, anemia, musculoskeletal pain, AST increase, ALT increase, dysphagia, and arthralgia. Clinically significant immune-related adverse events for patients receiving atezolizumab included pneumonitis, hepatitis, colitis, and thyroid disease.

“Tecentriq is a new option to help people with this type of previously treated metastatic lung cancer, regardless of PD-L1 expression, live longer than chemotherapy,” Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, the company that developed the drug, said in a statement. “Tecentriq is the first and only approved cancer immunotherapy designed to target the PD-L1 protein, which may play an important role in the way the medicine works.”

The drug continues to be evaluated as first-line treatment for lung cancer, alone or as part of a combination regimen.

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!